Mylan (MYL -0.1%) says its subsidiary Mylan Pharmaceuticals has reached a settlement with...
Wednesday, March 13, 4:02 PM ETMylan (MYL -0.1%) says its subsidiary Mylan Pharmaceuticals has reached a settlement with Shionogi and Andrx to resolve patent litigation related to the generic version of Shionogi's Fortamet, an adjunct to diet and exercise to lower blood glucose. The terms of the settlement agreement are confidential, but has been disclosed it that MYL may launch a generic version of Fortamet on August 1, 2013, or earlier under certain conditions.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles